AEterna Zentaris
1405 Boul Du Parc-technologique
Quebec
G1P 4P5
Canada
Tel: 418-652-8525
Fax: 418-652-0881
Website: http://www.aeternazentaris.com/
Email: aeterna@aeternazentaris.com
642 articles about AEterna Zentaris
-
Aeterna Zentaris and Ceapro Merger Approved by Securityholders at Special Meetings
3/12/2024
Aeterna Zentaris Inc. and Ceapro Inc. are pleased to announce that securityholders of both biopharmaceutical development companies approved the all-stock merger of equals transaction at their respective special meetings.
-
Leading Independent Proxy Advisory Firm ISS Recommends Aeterna Zentaris and Ceapro Securityholders Vote FOR the Arrangement Agreement to Approve the Merger of Equals to Create a Diversified Biopharmaceutical Company
2/26/2024
Aeterna Zentaris Inc. and Ceapro Inc., two innovative biopharmaceutical development companies, are pleased to announce that leading independent proxy advisor Institutional Shareholder Services Inc. recommended that both companies’ securityholders vote FOR the all-stock merger of equals transaction pursuant to the terms announced on December 14, 2023.
-
Ceapro Provides Business Update on Progress of Ongoing Development Programs, Technology and Cosmeceutical Base Business
2/23/2024
Ceapro Inc., provided an update on its progress across its current business.
-
Aeterna Zentaris Issues Letter to Shareholders and Management Proxy Circular Ahead of Special Meeting of Shareholders to Approve Merger of Equals with Ceapro
2/15/2024
Aeterna Zentaris Inc. announced that it has issued a Letter to Shareholders and Management Proxy Circular ahead of its special meeting of shareholders to approve its merger of equals transaction with Ceapro Inc.
-
Aeterna Zentaris and Ceapro Announce Merger of Equals to Create a Diversified Biopharmaceutical Company
12/14/2023
Aeterna Zentaris Inc. and Ceapro Inc., two innovative biopharmaceutical development companies, announced that they have entered into a definitive agreement to combine operations in an all-stock merger of equals transaction.
-
Aeterna Zentaris Reports Third Quarter 2023 Financial Results
11/9/2023
Aeterna Zentaris Inc. reported its financial and operating results for the quarter ended September 30, 2023.
-
Aeterna Zentaris to Participate at the Virtual Investor Ask the CEO Conference
10/11/2023
Aeterna Zentaris Inc. announced that Dr. Klaus Paulini, Chief Executive Officer of Aeterna Zentaris will participate at the Virtual Investor Ask the CEO Conference on Wednesday, October 25, 2023 at 10:00 AM ET.
-
Aeterna Zentaris to Present at the H.C. Wainwright 25th Annual Global Investment Conference
9/5/2023
Aeterna Zentaris Inc. today announced that Dr. Klaus Paulini, Chief Executive Officer of Aeterna, will present at the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023 in New York, NY.
-
Aeterna Zentaris Reports Second Quarter 2023 Financial Results
8/9/2023
Aeterna Zentaris Inc., a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, reported its financial and operating results for the quarter ended June 30, 2023.
-
Aeterna Zentaris Outlines Progress on Development Pipeline Programs and Provides Corporate Update
7/13/2023
Aeterna Zentaris Inc. today provided an update on its therapeutic and diagnostic development pipeline programs and outlined upcoming key milestones.
-
Aeterna Zentaris to Participate in the Virtual Investor Summer Spotlight Series
7/5/2023
Aeterna Zentaris Inc. today announced that Dr. Klaus Paulini, Chief Executive Officer and Eckhard Guenther, PhD, Managing Director and SVP, Business Development of Aeterna Zentaris, will participate in the Virtual Investor Summer Spotlight Series on Wednesday, July 13, 2023, at 10:00 AM ET.
-
Aeterna Zentaris Announces Results of Virtual 2023 Meeting of Shareholders
6/14/2023
Aeterna Zentaris Inc., a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, announced that all items of business were approved at its virtual Annual General and Special Meeting of Shareholders.
-
Aeterna Zentaris Announces Virtual 2023 Meeting of Shareholders
5/15/2023
Aeterna Zentaris Inc. announced that its Virtual Annual General and Special Meeting of Shareholders will be held on June 14, 2023, at 10:00 a.m..
-
Aeterna Zentaris Reports First Quarter 2023 Financial Results
5/9/2023
Aeterna Zentaris Inc., a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, reported its financial and operating results for the quarter ended March 31, 2023.
-
Aeterna Zentaris Provides Update on Macrilen® (Macimorelin), Reiterates Advancement of Pediatric DETECT Trial
4/5/2023
Aeterna Zentaris Inc. today announced that sales of Macrilen® (macimorelin) will be temporarily discontinued in the United States commercial market for the diagnosis of adult growth hormone deficiency (“AGHD”), effective May 23, 2023 and until anticipated re-launch with an alternate commercialization partner.
-
Aeterna Zentaris Reports Fourth Quarter and Full Year 2022 Financial Results
3/23/2023
Aeterna Zentaris Inc. today reported its financial and operating results for the year ended December 31, 2022.
-
Aeterna Zentaris Provides Business Update and Outlines Key Upcoming Milestones
1/17/2023
Aeterna Zentaris Inc., a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, provided a business update and outlined upcoming key milestones.
-
Aeterna Zentaris to Present at the Virtual Investor 2023 Companies to Watch Event
1/10/2023
Aeterna Zentaris Inc. today announced that Dr. Klaus Paulini, Chief Executive Officer of Aeterna Zentaris, will present at the Virtual Investor 2023 Companies to Watch Event on Thursday, January 19, 2023 at 3:00 PM ET.
-
Aeterna Zentaris Reports Third Quarter 2022 Financial Results
11/3/2022
Aeterna Zentaris Inc. reported its financial and operating results for the third quarter ended September 30, 2022.
-
Global Roundup: Clover Progresses Universal COVID-19 Booster, TikoMed Proves Platform in ALS
9/1/2022
Clover's SCB-2019 showed a robust immune response to the Omicron BA.5 sub-variant, while BrainsWay, TikoMed and more provide updates on their businesses and pipelines.